<DOC>
	<DOCNO>NCT01359878</DOCNO>
	<brief_summary>Severe maternal bleeding serious complication birth cause 125.000 death worldwide year . The investigator aim investigate early treatment fibrinogen concentrate versus saline reduce incidence blood transfusion woman postpartum haemorrhage . A low level fibrinogen associate increase blood loss transfusion requirement different clinical setting include obstetrical bleeding . Early up-front treatment fibrinogen may reduce incidence transfusion secure optimal haemostatic capacity woman postpartum haemorrhage . The investigator plan enrol 245 patient four hospital Capital Region Denmark two year period . As safety measure investigator plan use TEG®/Functional Fibrinogen/Rapid-TEG haemostatic monitoring participant trial : Baseline test take inclusion administration fibrinogen concentrate/placebo . Further test take immediately intervention , 4 hour 24 hour . Baseline test blind provider treatment - rest clinically available .</brief_summary>
	<brief_title>Fibrinogen Concentrate Initial Treatment Postpartum Haemorrhage : A Randomised Clinically Controlled Trial</brief_title>
	<detailed_description>Experimental design Design : We plan conduct randomised double-blinded clinically control trial : The participant assign either 1 ) placebo ( 100 ml isotonic saline ) i.v . 2 ) intervention drug : 2 g fibrinogen concentrate ( Haemocomplettan , CSL Behring ) i.v . We intend use fix dose patient randomize intervention group without prior measurement fibrinogen level . This strategy primarily base clinical urgency since treatment require administer early possible . Materials duration study Patients include two year period four large hospital Capital Region : Rigshospitalet , Hvidovre , Hillerød Herlev fulfil follow eligibility criterion Plan trial execution In order secure ethical aspect `` Time reflection '' provide pregnant woman appear centre trial period write information trial midwife evaluation . Only 1,75 % woman estimate meet inclusion criterion postpartum . Intensive haemostatic monitoring Haemostatic blood sample include thrombelastography ( TEG® ) , functional fibrinogen-assay TEG® , Rapid-TEG , fibrinogen-level , d-Dimer , INR ( international normalize ratio ) , platelet count Antithrombin III draw 15 minute intervention give , 4 hour 24 hour later . The sample take intervention fully available evaluation clinician responsible patient . The patient observe blood pressure , pulseoximetry , ECG possible side effect re-bleeding evaluated . Follow The patient remain hospitalized minimum 24 hour . We contact participant phone six week intervention . Upon discharge hospital , include patient receive information-material address possible late side effect contact number .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Postpartum Hemorrhage</mesh_term>
	<criteria>1 . Informed consent participant . 2 . Women develop PPH define bleed uterus and/or birth canal within 24 hour postpartum . 3 . Age ≥ 18 year . 4 . If vaginal birth : indication one following procedure operation theatre anaesthetic assistance : ) Estimated blood loss ≥ 500 ml indication manual removal placenta b ) Indication manual exploration uterus due continuous bleed birth placenta . 5 . If birth Caesarean section : A perioperative blood loss ≥ 1000 ml . 1 . Patients know inherited deficiency coagulation . 2 . Patients antithrombotic treatment prepartum due increase risk thrombosis . 3 . Patients prepregnancy weight &lt; 45 kg . 4 . Patients refuse receive blood transfusion .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Postpartum haemorrhage</keyword>
	<keyword>Postpartum bleeding</keyword>
	<keyword>Postnatal bleeding</keyword>
	<keyword>Fibrinogen concentrate</keyword>
	<keyword>Transfusion</keyword>
	<keyword>Haemostatis</keyword>
	<keyword>Thrombelastography</keyword>
</DOC>